EUMCA News 

An in-depth look at medical cannabis from EUMCA Chairman Professor Trevor Jones For many centuries, nature’s pharmacy has been an important source of potent therapeutic agents; either by administering parts of plants, eg opium and senna pods, or preparing...

Professor Trevor Jones CBE FMedSci, says: “CBD is NOT a narcotic.  The uncertainty about the legal status CBD, especially of plant-derived CBD, is a barrier to its medical use.” Professor Trevor Jones, Chair of the EUMCA urges the Commission to agree to the WHO...

Founding member of the EUMCA Tilray has reported that a clinical trial on its GMP medicinal cannabis product shows promise of reducing nausea and vomiting caused by chemotherapy. The results, published in the Annals of Oncology, found a significant improvement in the...

License marks commencement of European cultivation activities and establishes Portugal as Clever Leaves’ European medical cannabis production hub New York, Lisbon, August 25, 2020 – Clever Leaves (the “Company”), a leading multi-national operator and licensed producer...

Professor Trevor Jones CBE FMedSci, chair of the EUMCA, says “As a result, quality standards may vary in each country in the absence of an overarching benchmark for quality at EU level. Building a homogeneous set of quality standards for medical cannabis is crucial...

“Patients should have the right to know what they are buying or being prescribed is of proper quality. Currently, there is no real agreement on what analytical methodology should be used to check the quality nor what standards we should set, for instance, for CBD. My...